Table 1.
Characteristics of Ppatients at Llisting and at the Ttime of Ttransplant
| End-stage Cirrhosis | HCC1* | Acute Liver Failure | All | P value | |
|---|---|---|---|---|---|
| No of patients | 73 (39.3) | 97 (51.8) | 17 (8.9) | 187 (100) | |
| Gender, male | 58 (79.5) | 75 (77.3) | 8 (47.1) | 141 (75.4) | 0.013 |
| Age, years | 50.6 ± 8.1 | 55.5 ± 9.6 | 43.0 ± 14.2 | 52.4 ± 10.2 | 0.001 |
| Race | 0.005 | ||||
| Caucasian | 33 (45.2) | 36 (37.1) | 9 (53.0) | 78 (41.7) | |
| Asian | 23 (31.5) | 53 (54.6) | 4 (23.5) | 80 (42.8) | |
| African American | 10 (13.7) | 5 (5.2) | 4 (23.5) | 19 (10.2) | |
| Other | 7 (9.6) | 3 (3.1) | 0(0) | 10 (5.3) | |
| Labs at listing | |||||
| HBeAg (+) | 20/67 (29.8) | 25/84 (29.7) | 6/14 (42.9) | 51/165 (30.9) | 0.600 |
| HBV DNA detectable | 31/66 (47.0) | 42/85 (49.4) | 8/17 (47.1) | 81/168 (48.2) | 0.952 |
| HBV DNA >5 log10 copies/mL | 16/66 (24.2) | 31/85 (36.5) | 4/17 (23.5) | 51/168 (30.4) | 0.218 |
| CTP Score | 9.7 ± 2.2 | 7.7 ± 2.5 | 12.0 ± 1.7 | 9.1 ± 2.6 | <0.001 |
| Lab MELD | 19.7 ± 8.7 | 13.1 ± 7.1 | 30.4 ± 5.9 | 18.4 ± 9.1 | <0.001 |
| Anti-HCV (+) | 5/66 (7.6) | 5/81 (6.2) | 0/17 (0) | 10/164 (6.1) | 0.507 |
| Anti-HDV (+) | 3/25 (12.0) | 1/23 (4.3) | 0/5 (0) | 4/53 (7.5) | 0.483 |
| Time on the waiting list, months | 5 (0.1–84.0) | 3 (0.1–97.5) | 0.06 (0.03–0.27) | 3.0 (0.03–97.5) | 0.034 |
| Labs at transplantation | |||||
| HBeAg (+) | 18/63 (28.6) | 21/79 (26.6) | 5/12 (41.7) | 44/154 (28.6) | 0.559 |
| HBV DNA detectable | 48/68 (70.6) | 45/80 (56.3) | 13/17 (76.5) | 106/165 (64.2) | 0.104 |
| HBV-DNA >5 log10 copies/mL | 22/68 (32.3) | 33/80 (41.3) | 7/17 (41.2) | 62/165 (37.5) | 0..077 |
| HBV DNA >3 log10 copies/mL | 35/68 (51.5) | 39/80 (48.7) | 12/17 (70.5) | 86/165 (52.1) | 0.259 |
| HBV-DNA, log10 copies/mL | 4.0 ± 2.2 | 4.1 ± 2.2 | 4.6 ± 2.1 | 4.1 ± 2.2 | 0.651 |
| Albumin, g/dL | 2.6 ± 0.6 | 3.2 ± 0.7 | 2.7 ± 0.6 | 2.9 ± 0.7 | <0.001 |
| AST, U/L | 337 ± 862 | 154 ± 322 | 1212 ± 2133 | 323 ± 909 | <0.001 |
| ALT, U/L | 258 ± 675 | 108 ± 203 | 1261 ± 2158 | 273 ± 841 | <0.001 |
| Bilirubin, mg/dL | 10.4 ± 12.4 | 2.9 ± 5.4 | 20.7 ± 9.6 | 7.5 ± 10.7 | <0.001 |
| Alkaline phosphatase, U/L | 146 ± 80.5 | 155 ± 111 | 137 ± 56.3 | 150 ± 96.0 | 0.716 |
| INR | 2.1 ± 1.5 | 1.3 ± 0.5 | 3.0 ± 1.7 | 1.8 ± 1.2 | <0.001 |
| CTP Score | 11.8 ± 3.1 | 7.7 ± 2.5 | 13 ± 1.4 | 10.1 ± 3.4 | 0.001 |
| Lab MELD | 24.5 ± 10.1 | 15.4 ± 8.1 | 32.1 ± 5.8 | 24.0 ± 9.5 | <0.001 |
| AFP, ng/mL | 39.7 ± 215 | 453 ± 1538 | 68 ± 98 | 286 ± 1206 | <0.001 |
| Antiviral treatment at transplantation | 56 (76.7) | 75 (77.3) | 7 (41.2) | 138 (73.8) | 0.006 |
| Duration of antiviral treatment prior to OLT, months | 19.8 ± 21.0 | 23.3 ± 21.8 | 0.1 ± 0.3 | 20.7 ± 21.4 | 0.021 |
| Types of treatment | 0.072 | ||||
| LAM | 39 | 48 | 7 | 94 | |
| ADV | 3 | 12 | 0 | 15 | |
| ETV | 0 | 4 | 0 | 4 | |
| TDF | 4 | 0 | 0 | 4 | |
| LAM+ADV | 10 | 6 | 0 | 16 | |
| LAM+TDF | 0 | 2 | 0 | 2 | |
| ETV+ADV | 0 | 2 | 0 | 2 | |
| TDF+ADV | 0 | 1 | 0 | 1 | |
| Virologic breakthrough prior to OLT | 12/56(21.4) | 13/75(17.3) | 0/7(0) | 25/138(18.1) | 0.200 |
| LAM | 11 | 11 | 0 | 22 | |
| ADV | 0 | 1 | 0 | 1 | |
| LAM+ADV | 1 | 1 | 0 | 2 |
Results expressed as number (%) or mean ± SD unless specified otherwise
LAM: Lamivudine, ADV: Adefovir, TDF: Tenofovir, ETV: entecavir
HCC = Hepatocellular carcinoma;, CTP: = Child Turcotte Pugh; MELD = Model for Endstage Liver Disease
AST: aspartate aminotransferase, ALT: alanine aminotransferase
1
Patients found to have HCC while on the waiting list or at transplant were included in the HCC column